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Purpose:  Although  ischemia  has  previously  been  suggested  to  contribute  to  the  pathogenesis  of  glaucoma,
neovascularization is not implicated in glaucoma. Because vascular endothelial growth factor-A (VEGF-A) is a key
mediator in neovascularization response, we investigated the levels of the major pro-angiogenic (VEGF-A164) and anti-
angiogenic VEGF-A subtypes (VEGF-A165b) in the retina during experimental glaucoma.
Methods: Glaucoma was induced unilaterally in rats by injecting 1.9 M hypertonic saline solution in the episcleral veins.
The contralateral eye served as the control. The intraocular pressure (IOP) of each eye was measured via Tonopen in
conscious rats. Eyes were enucleated either on the 5th or the 10th day of elevated IOP. Whole retinal lysates were separated
by SDS–PAGE and transferred to PVDF membranes. Levels of VEGF-A164 and VEGF-A165b were analyzed by western
blotting using specific antibodies. In a different group of rats, retinal ganglion cells were retrogradely labeled by injecting
Fluorogold in the superior colliculus a week before the induction of glaucoma. After the eyes were enucleated on the fifth
day of elevated IOP, posterior eye cups were sectioned using a cryostat. Levels and localization of VEGF-A164 and VEGF-
A165b were examined in retinal sections by immunohistochemistry.
Results: VEGF-A164 levels remained unchanged between the control and glaucomatous retinas after five days (p=0.341)
and 10 days of elevated IOP (p=0.117). The presence of the anti-angiogenic VEGF-A isoform has not been previously
reported in the rat. An antibody specific to VEGF-A165b detected the anti-angiogenic protein in the rat retina. VEGF-
A165b levels were significantly increased (2.33±0.44 fold, p=0.014) in the glaucomatous retinas compared to those in
controls after five days of elevated IOP. VEGF-A165b levels were not different (p=0.864) between the control and
glaucomatous retinas following 10 days of elevated IOP. Expression of both VEGF-A164 and VEGF-A165b were observed
in the retinal ganglion cells (RGC) and inner nuclear layer (INL).
Conclusions: Five day elevation of IOP leads to an increase in the anti-angiogenic VEGF-A165b levels but not in the pro-
angiogenic VEGF-A164 levels in the glaucomatous retina. VEGF-A165b levels return to baseline after 10 days of elevated
IOP, and VEGF-A164 levels remain unchanged. We speculate that the short-term elevation of VEGF-A165b levels and/or
the unchanged levels of VEGF-A164 contribute to the lack of neovascularization in the glaucomatous retina.
Glaucoma  is  a  neurodegenerative  disease  of  retinal
ganglion cells (RGC) that leads to blindness. Although the
most prominent risk factor for RGC death in glaucoma is
elevated intraocular pressure (IOP), the sequence of events by
which IOP causes RGC death still remains largely unknown.
One  possible  mechanism  is  that  elevated  IOP  can  induce
abnormalities in blood flow in the glaucomatous eye. In open-
angle glaucoma patients, abnormal vascular autoregulation
has been observed in the inferior temporal retinal artery, the
central retinal artery, the circulation of the optic nerve head,
the choroid, and the perifoveal macular capillaries [1-8]. It has
been suggested that dysregulation of blood flow may lead to
decreased vascular perfusion in the retina and in the optic
nerve head, resulting in an hypoxic response [9,10].
Correspondence to: Cynthia L. Grosskreutz, Howe Laboratory of
Ophthalmology,  Massachusetts  Eye  and  Ear  Infirmary,  Harvard
Medical School, 243 Charles Street, Boston, MA, 02114; Phone:
(617)  573-4328;  FAX:  (617)  573-4300;  email:
cynthia_grosskreutz@meei.harvard.edu
In  the  classical  view  of  hypoxia,  the  ischemic  tissue
compensates for a decrease in oxygen levels by forming new
blood vessels, a process known as neovascularization [11].
VEGF-A is a key mediator in neovascularization in ischemic
retinopathies [12-14]. There are several VEGF-A isoforms
expressed from a single gene via alternative splicing [15,16].
Among these, VEGF-A165 is the most abundantly expressed
pro-angiogenic isoform in the retina [17]. More recently, anti-
angiogenic  sister  isoforms  of  VEGF-A  have  also  been
identified  [18-20].  For  example,  VEGF-A165b,  an  anti-
angiogenic  human  VEGF-A  isoform,  has  been  shown  to
inhibit  VEGF-A  induced  neovascularization  in  the  mouse
retina following ischemia [21].
There are only a few studies that have examined VEGF-
A in glaucoma. VEGF levels were shown to be increased in
the plasma of glaucoma patients when compared to that of
healthy controls [22] and in the aqueous humor of glaucoma
patients when compared to their plasma VEGF levels [23].
Despite these findings, neovascularization is not implicated
Molecular Vision 2008; 14:1517-1524 <http://www.molvis.org/molvis/v14/a181>
Received 16 July 2008 | Accepted 14 August 2008 | Published 18 August 2008
© 2008 Molecular Vision
1517in glaucoma, and the role of VEGF-A has not been examined
in the glaucomatous retina.
If ischemia contributes to the pathogenesis of glaucoma,
why is there no neovascularization in glaucoma? To answer
this  apparent  paradox,  we  investigated  the  levels  of  pro-
angiogenic VEGF-A164 (the rat version of VEGF-A165) and
anti-angiogenic VEGF-A165b (the rat version of VEGF-A165b)
in normal and glaucomatous retinas after a short-term (five
day) and an intermediate-term (10 day) elevation of IOP.
Because of the lack of neovascularization in glaucoma, we
hypothesized that the levels of VEGF-A165b but not VEGF-
A164 would be increased in the glaucomatous retina.
METHODS
Subjects: Male rats (retired breeder Brown Norway; 300-450
g; n=16) were used for the study. Rats had ad libitum access
to food and water during the study and were kept on a 12 h
illumination  cycle.  All  animal  related  procedures  were
performed in accordance with the statement for the use of
animals in research released by the Association for Research
in Vision and Ophthalmology.
Retrograde labeling of retinal ganglion cells: Rats (n=4) were
anesthetized with an intraperitoneal injection of 1.5 mg/kg of
acepromazine maleate, 7.5 mg/kg of xylazine, and 75 mg/kg
of  ketamine  (Webster  Veterinary  Supply,  Sterling,  MA).
Following  shaving  of  the  head,  each  rat  was  placed  in  a
stereotaxic  instrument.  The  skin  covering  the  skull  was
incised along the midline using a surgical blade, and the skull
was exposed and leveled. Next, for each hemisphere, a 30-
gauge stainless steel needle was lowered into the superior
colliculus at 5.3 mm posterior to the bregma, 1.5 mm lateral
to the midline, and 4.8 mm ventral to the skull surface. Using
a 5 μl syringe (Hamilton, Reno, NV), 2 μl of Fluorogold
solution  (3%  in  PBS  with  10%  DMSO;  Fluorochrome,
Denver, CO) was injected over 10 min into each hemisphere.
Following the injections, the skin was sutured. Rats were
allowed to recover for a week before glaucoma was induced
experimentally.
Experimental  induction  of  glaucoma:  To  elevate  IOP,
hypertonic saline solution (1.9 M) was unilaterally injected in
the episcleral veins as described by Morrison and colleagues
[24]. The contralateral eye of the rat served as the control. A
maximum number of three injections that were two weeks
apart were performed in the absence of IOP elevation. Rats
that did not have an elevation of IOP after the third surgery
were excluded from the study.
Intraocular  pressure  measurements:  IOPs  were  measured
with  a  TonoPen  XL  tonometer  (Medtronic  Ophthalmics,
Jacksonville, FL) in conscious rats [25]. Measurements were
taken between 10 AM and 2 PM. Before the first hypertonic
saline injection, baseline IOPs for both eyes were measured
for each rat. Following glaucoma inducing surgery, IOPs were
measured three times a week. On each measurement day, an
average of 15 readings was calculated for each eye. This study
investigated a five day (n=6) and a 10 day elevation of IOP
(n=6).
Tissue preparation: Rats were sacrificed by CO2 inhalation
either after five days or 10 days of elevated IOP. For western
blotting, retinas were isolated from eyes obtained after five
days and 10 days of elevated IOP (six pairs each). Retinas
were placed in 200 μl of 1 mM of EDTA/EGTA/DTT, 10 mM
of Hepes (pH=7.6), 0.5% Igepal (Sigma Chemical Co., St.
Louis, MO), 42 mM of KCl, 5 mM of MgCl2, 1 mM of PMSF,
and a tablet of protease inhibitors (Complete Mini, Roche
Diagnostics,  Mannheim,  Germany).  After  retinas  were
sonicated and incubated for 15 min on ice, samples were spun
at 21,000 rpm at 4 °C for 30 min. Retinal proteins were
quantified by spectrophotometry using the Bio-Rad Dc Protein
Assay (Bio-Rad Laboratories, Hercules, CA).
For immunohistochemistry, four pairs of eyes that were
enucleated after five days of elevated IOP were fixed with 4%
paraformaldehyde for 20 min at room temperature. These eyes
were  previously  back-labeled  with  Fluorogold.  Next,  the
posterior  eye  cups  were  isolated  and  fixed  with  4%
paraformaldehyde  for  an  additional  40  min  at  room
temperature.  After  posterior  eye  cups  were  cryoprotected
overnight in graded sucrose dilutions, they were placed in the
optimal  cutting  temperature  compound  (Tissue-tek,  Miles
Diagnostic Division, Elkhart, IN) and were sectioned 16 μm
thick using a cryostat.
Western blotting: Retinal proteins isolated after either five
days or 10 days of elevated IOP were separated on Tris-HCl
Ready-Gels  (Bio-Rad  Laboratories,  Hercules,  CA).
Recombinant  rat  VEGF-A164  protein  (25–250  ng;  R&D
Systems, Minneapolis, MN) was also loaded as a positive
control in certain experiments. Proteins separated by SDS–
PAGE  were  then  transferred  to  polyvinylidene  difluoride
membranes (Immobilon-P; Millipore, Billerica, MA) for 1 h.
After the membrane was blocked for 1 h at room temperature
with  2%  ECL  Advance  Blocking  Agent  (GE  Healthcare,
Piscataway, NJ) in Tris-buffered saline with Tween (TBS-T),
it was incubated at 4 °C overnight with a primary antibody.
The primary antibodies used in this study were as follows:
rabbit  polyclonal  anti-VEGF  (1:50;  Santa  Cruz
Biotechnology, Santa Cruz, CA), mouse monoclonal anti-
VEGF165B (1:1,000; Abcam, Cambridge, MA), and mouse
monoclonal anti-α-tubulin (1:100,000; Sigma, Saint Louis,
MO). The next day, membranes were incubated for 1 h at room
temperature  with  peroxidase-conjugated  secondary
antibodies. Goat anti-rabbit IgG (1:10,000–1:40,000; Jackson
ImmunoResearch, West Grove, PA) and goat anti-mouse IgG
(1:20,000–1:100,000;  Jackson  ImmunoResearch)  were  the
secondary  antibodies  used  in  the  study.  Both  of  these
antibodies had minimal cross-reaction to rat serum proteins.
Next, membranes were processed with ECL Advance Western
Blotting Detection Kit (GE Healthcare, Piscataway, NJ) and
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Inc., Rochester, NY).
Densitometry  and  statistical  analysis:  A  Personal
Densitometer SI (Molecular Dynamics, Sunnyvale, CA) was
used to scan the exposed films. The density of the protein of
interest  on  the  film  was  measured  using  ImageQuant  1.2
(Molecular  Dynamics).  First,  the  background  density  was
subtracted  from  the  density  of  each  band.  Next,  the
densitometric  reading  of  the  protein  of  interest  was
normalized to α-tubulin readings, which served as loading
controls. For each retina pair, the normalized densitometric
reading from the glaucomatous retina was divided by the
reading from the control retina. Then, the ratios from different
pairs of retinas were averaged. For statistical analysis, a one-
sample t-test was used to evaluate the significance of the ratios
for  a  given  protein  (one-tailed,  hypothesized  mean=1,  α
level=0.05). Data were reported as mean±standard error of the
mean (SEM) in the text.
Immunohistochemistry: Retinal sections from four pairs of
eyes were blocked for 1 h at room temperature in 4% normal
goat  serum  and  0.3%  Triton-X  100  in  1X  PBS,  pH  7.4.
Sections were incubated with the primary antibody overnight
at 4 °C. Some sections were incubated in blocking solution
without  the  primary  antibody  and  were  used  as  negative
controls. The primary antibodies and the dilutions used in the
study were mouse monoclonal anti-VEGF (20 μg/ml; Sigma)
and mouse monoclonal anti-VEGF165B (1:500; Abcam). The
following day, sections were incubated with the Alexa Fluor
594-conjugated goat anti-mouse secondary antibody (1:500;
Invitrogen, Carlsbad, CA) for 1 h at room temperature. After
the sections were treated with Prolong Gold anti-fade reagent,
staining was visualized using an Olympus BX51 microscope
(Olympus, Center Valley, PA).
On our BX51 microscope, we used UPlanApo 0.70 NA
20X  (Olympus)  and  UPlanApo  0.85  NA  40X  (Olympus)
objective lenses through a 10X ocular or camera lens to image
our retinal sections for a total magnification of 200X or 400X,
respectively. Excitation/emission filter cubes used for a given
fluorophore were 11006v2 Gold (Chroma, Rockingham, VT)
for Fluorogold and N41004 HQ Texas Red (Chroma) for
Alexa Fluor 594. We used DPController 1.2.1.108 (Olympus)
in conjunction with the DP70 color camera (Olympus) affixed
to the BX51 to image the retinal sections for fluorescence. We
then used Adobe Photoshop to layer the images and apply
transparency to see the overlap of different fluorophores in a
given section area.
RESULTS
Levels  of  VEGF-A164  do  not  change  in  the  glaucomatous
retina: Average peak IOP was (mean±SEM) 40.7±1.9 mmHg
and 43.1±0.8 mmHg for the five-day (n=6) and 10-day (n=6)
groups that were used in the western blot (WB) analysis,
respectively. Average peak IOP was 43.4±0.8 mmHg for the
other  five-day  group  used  for  the  immunohistochemistry
(IHC) analysis (n=4).
In western blots, anti-VEGF antibody detected a 45 kDa
band corresponding to the VEGF-A164 dimer in all retinas and
in the positive control brain (Figure 1). VEGF-A164 levels
remained unchanged between the control and glaucomatous
retinas after five days (p=0.341, n=6; Figure 1A,C) and 10
days of elevated IOP (p=0.117, n=6; Figure 1B,C). Using this
well characterized antibody [26,27], the VEGF-A164 monomer
was not detected in the retina or in the brain.
In VEGF-A164 IHC, there was some nonspecific staining
in the blood vessels in the RGC layer and INL of the negative
control retinas (Figure 2B,C). VEGF-A164 staining did not
differ  between  the  normal  (Figure  2E)  and  glaucomatous
retinas (Figure 2H). VEGF-A164 expression was localized to
the RGC and the cells in the INL of both groups (Figure 2E,H).
In the RGC layer, VEGF-A164 staining colocalized with the
retinal ganglion cell marker, Fluorogold (Figure 2F,I). Also,
VEGF-A164  levels  did  not  differ  between  the  normal  and
glaucomatous  retinas,  which  are  consistent  with  the  WB
results.
Anti-VEGF-A165b  antibody  does  not  recognize  VEGF-A164:
Because it had been predicted that VEGF-A164 and VEGF-
A165b are highly homologous in amino acid sequence [18], we
first  investigated  whether  the  anti-VEGF-A165b  antibody
would also recognize VEGF-A164. To test this possibility, we
immunoblotted different concentrations (25 ng, 100 ng, and
250 ng) of the recombinant rat VEGF-A164 protein with the
anti-VEGF-A165b  antibody.  Whereas  the  anti-VEGF-A165b
antibody did not recognize the VEGF-A164 protein at any
concentration,  it  recognized  two  bands  around  22.4  and
45  kDa  in  a  pair  of  control  and  glaucomatous  retinas
corresponding to the monomer and dimer forms of VEGF-
A165b,  respectively  (Figure  3A).  Next,  we  stripped  the
Figure 1. Western blot analysis of VEGF-A164 expression in the
glaucomatous  retina.  A:  VEGF-A164  was  detected  at  45  kDa  in
control and glaucomatous retinas after five days of elevated IOP.
B: Similarly, VEGF-A164 was observed at 45 kDa in the control and
glaucomatous  retinas  following  10  days  of  elevated  IOP.  C:
Glaucomatous/control ratio of normalized VEGF-A164 densitometry
readings in the retina is demonstrated in the chart. VEGF-A164 was
expressed at comparable levels in the control and glaucomatous
retinas after five and 10 days of elevated IOP. The positive control
was the brain, and the loading control was α-tubulin.
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1519membrane and subsequently immunoblotted with the anti-
VEGF  antibody.  A  22.4  kDa  VEGF-A164  monomer  was
detected at all concentrations (Figure 3B), confirming the
presence  of  VEGF-A164  recombinant  protein  in  the  same
membrane.  The  dimer  form  was  not  observed  with  the
recombinant rat VEGF-A164 protein. The combination of these
findings indicated that the anti-VEGF-A165b antibody does not
recognize VEGF-A164 and that VEGF-A165b is expressed in the
rat retina.
VEGF-A165b levels are increased in the glaucomatous retina:
Following five days of elevated IOP, the anti-VEGF-A165b
antibody detected bands around 22.4 and 45 kDa in all retinas,
which represent the monomer and dimer forms of VEGF-
A165b, respectively (Figure 4A). Whereas VEGF-A165b dimer
levels  remained  unchanged  between  the  control  and
glaucomatous retinas (p=0.273, n=6), VEGF-A165b monomer
levels  were  significantly  increased  in  the  glaucomatous
retinas  compared  to  those  in  controls  (2.33±0.44  fold,
p=0.014, n=6) (Figure 4A,B). However, following 10 days of
elevated IOP, there was no change in levels for the VEGF-
A165b dimer (p=0.483, n=6) or for the VEGF-A165b monomer
(p=0.864, n=6) between the control and glaucomatous retinas
Figure 3. Anti-VEGF-A165b antibody does not recognize VEGF-
A164.  A:  Incubation  with  VEGF-A165b  antibody.  This  antibody
recognizes the VEGF-A165b monomer (22.5 kDa) and dimer (45 kDa)
in control and glaucomatous retinas (first two lanes). VEGF-A165b
antibody does not recognize 25 ng, 100 ng, or 250 ng of VEGF-
A164 recombinant protein in the same membrane (last three lanes).
B: Incubation of the same membrane with the anti-VEGF antibody
after  stripping.  The  anti-VEGF  antibody  recognizes  VEGF-A164
recombinant protein at all concentrations.
Figure  2.  Immunohistochemical
analysis of VEGF-A164 expression in the
glaucomatous retina after five days of
elevated  IOP.  A-C:  Negative  control.
Some  non-specific  staining  of  blood
vessels in the RGC and the INL was
observed. D-F: VEGF-A164 staining of
the normal retina (n=4). VEGF-A164 was
present in the RGC and the INL. G-I:
VEGF-A164  staining  of  the
glaucomatous retina (n=4). Staining was
detected in the RGC and INL. VEGF-
A164 levels did not differ between the
normal and glaucomatous retinas.
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increase after five days of elevated IOP and return to baseline
levels after 10 days of elevated IOP.
IHC demonstrated that the distribution of VEGF-A165b
was similar to that of VEGF-A164. VEGF-A165b staining was
observed in the RGC and in the inner nuclear layer (Figure
5E,H). In the RGC layer, staining overlapped with the RGC
marker,  Fluorogold  (Figure  5F,I,O,R).  No  staining  was
observed in the negative control with the primary antibody
omitted (Figure 5B,K). Consistent with our WB results, IHC
analysis  showed  increased  levels  of  VEGF-A165b
immunoreactivity in the glaucomatous retinas compared to
normal  retinas  (Figure  5H,Q  verses  Figure  5E,N,
respectively).
DISCUSSION
We demonstrate in this report that VEGF-A165b is present in
the rat. In particular, we show that VEGF-A165b is present in
the retina and localized primarily to the RGC layer and the
Figure 4. Western blot analysis of VEGF-A165b expression in the
glaucomatous retina. A: VEGF-A165b expression following five days
of elevated IOP. Retinal VEGF-A165b monomer and dimer were
detected at 22.5 and 45 kDa, respectively. B: Glaucomatous/control
ratio of normalized VEGF-A165b densitometry readings in the retina
following five days of elevated IOP. Expression of the 22.5 kDa
VEGF-A165b was increased significantly in the glaucomatous retinas
compared to the controls. C: VEGF-A165b expression following 10
days  of  elevated  IOP.  VEGF-A165b  monomer  and  dimer  were
observed  at  22.5  and  45  kDa  in  the  retina,  respectively.  D:
Glaucomatous/control  ratio  of  normalized  VEGF-A165b
densitometry readings in the retina following 10 days of elevated
IOP. Both 22.5 kDa and 45 kDa VEGF-A165b were expressed at
comparable  levels  in  the  control  and  glaucomatous  retinas.  The
positive control was the brain while the negative control was VEGF-
A164 recombinant protein. The loading control was α-tubulin.
inner  nuclear  layer.  Our  findings  for  VEGF-A165b  show  a
distribution similar to that seen for VEGF-A164 in this report
and  previous  reports  about  VEGF-A164  by  others  [28,29].
Using back labeling techniques, we find that RGC express
VEGF-A165b.  Our  data  show  that  VEGF-A165b  levels  are
increased early in the cause of experimental glaucoma but
return to baseline at a later time point. IHC results show that
this increase is primarily due to increased expression in the
RGC layer and in the INL.
Our  results  demonstrate  that  the  levels  for  the  pro-
angiogenic VEGF-A164 do not change in the glaucomatous
retina compared to control retinas in the rat after five days or
10 days of elevated IOP. Consistent with previous studies, we
observe that VEGF-A164 is expressed in the RGC and INL of
the retina [28,29].
VEGF-A165  is  the  most  abundantly  expressed  pro-
angiogenic isoform in the retina [17]. Both VEGF-A165 and
VEGF-A165b  mRNA  are  produced  from  the  VEGF-A  pre-
mRNA  via  alternative  splicing  [15,18].  VEGF-A165  and
VEGF-A165b share a 96.4% homology and differ only in the
last six amino acids in their amino acid sequence in humans
[18]. However, while VEGF-A165 is pro-angiogenic, VEGF-
A165b has an inhibitory effect on angiogenesis both in vitro and
in  vivo  [18,19].  For  example,  VEGF-A165b  inhibits
neovascularization  in  the  mouse  retina  following  oxygen-
induced  retinopathy  [21].  More  recently,  other  inhibitory
splice variants of VEGF-A have also been identified [19,20].
It  has  been  suggested  that  the  relative  levels  of  the  pro-
angiogenic and anti-angiogenic VEGF-A isoforms determine
whether angiogenesis will be stimulated or inhibited in a tissue
[20].  For  instance,  the  expression  of  the  pro-angiogenic
VEGF-A isoforms increases in the vitreous of human patients
with diabetic retinopathy whereas the expression of the anti-
angiogenic VEGF-A isoforms remains unchanged compared
to  the  normal  vitreous  [20].  Among  the  anti-angiogenic
VEGF-A  isoforms,  VEGF-A165b  is  observed  to  be  the
dominant isoform [15,18].
What  molecular  mechanism  is  responsible  for  the
upregulation  of  VEGF-A165b  mRNA  in  the  glaucomatous
retina?  Although  the  precise  answer  remains  unknown,
proposed mechanisms include differential promoter selection,
alternate  regulation  of  mRNA  stability,  and  regulation  of
alternative splicing [15,30-33]. In alternative splicing, as the
VEGF-A gene is being transcribed, the emerging pre-mRNA
is instantaneously processed by several RNA-binding proteins
and splice factors [15]. These proteins bind to the auxiliary
sequences on the pre-mRNA and determine which exons will
be spliced [34]. It is thought that several signal transduction
pathways, which are activated in response to changes in the
environment  (e.g.,  receptor-mediated  pathways,  neuronal
activity,  cellular  stress-like  hypoxia)  affect  alternative
splicing  by  altering  the  relative  levels  of  RNA-binding
proteins and splice factors or the localization of splice factors
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1521within the cell [15,35,36]. More recently, microRNAs have
also  been  shown  to  alter  alternative  splicing  [37].  For
example, in muscle and neuronal development, microRNAs
lead to the inclusion of alternative exons by suppressing a
repressor protein of alternative splicing [38,39]. In addition,
transcriptional  events  may  also  affect  the  regulation  of
alternative  splicing.  For  instance,  the  speed  of  RNA
polymerase II can influence the choice of splice sites and
recruitment of regulatory factors [40].
In conclusion, we report an increase in the retinal levels
of the anti-angiogenic VEGF-A165b but not the pro-angiogenic
VEGF-A164  in  our  experimental  glaucoma  model.  The
combination of these findings suggests that the elevation of
VEGF-A165b levels and/or the unchanged levels of VEGF-
A164 contribute to the lack of neovascularization in the retina
in glaucoma.
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glaucomatous retina. Levels of VEGF-A165b in the Fluorogold-labeled RGC (white arrow) were increased in the retinas with elevated IOP.
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